Pembrolizumab-Induced Isolated Cranial Neuropathy: A Rare Case Report and Review of Literature

Introduction: Anti-PD1 agents are widely used in the treatment of solid tumors. This has prompted the recognition of a class of immune-related adverse events (irAEs), due to the activation of autoimmune T-cells. Pembrolizumab is an anti-PD1 agent, which has been related to an increased risk of vario...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruno, Francesco, Palmiero, Rosa Antonietta, Ferrero, Bruno, Franchino, Federica, Pellerino, Alessia, Milanesi, Enrica, Soffietti, Riccardo, Rudà, Roberta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144636/
https://www.ncbi.nlm.nih.gov/pubmed/34046006
http://dx.doi.org/10.3389/fneur.2021.669493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144636/
https://www.ncbi.nlm.nih.gov/pubmed/34046006
http://dx.doi.org/10.3389/fneur.2021.669493

Ejemplares similares